New Codes for Cytokine Release Syndrome (CRS)

October 1st, 2020 - Wyn Staheli, Director of Research
Categories:   Diagnosis Coding   Allergy|Immunology   Anesthesia|Pain Management   Cardiology|Vascular   Endocrinology   Home Health|Hospice   Neurology|Neurosurgery   Oncology|Hematology   Rheumatology  
0 Votes - Sign in to vote or comment.

Cytokine release syndrome (CRS), sometimes referred to as a cytokine storm, is a systemic inflammatory response triggered by a variety of reasons such as infections, certain drugs, or after treatment with some types of immunotherapy, (e.g., monoclonal antibodies and CAR-T cells).  It is characterized by a large, rapid release of cytokines into the blood. Cytokines are small proteins that help cells around the body communicate. When the immune system detects a threat, cells release cytokines to coordinate the body’s response. Too many cytokines cause harmful levels of inflammation throughout the body. Symptoms of CRS may include nausea, headache, tachycardia, hypotension, rash, shortness of breath, or in severe cases, death.

Chimeric Antigen Receptor T (CAR-T) Cell Therapy is an advancement in the treatment of relapsed or refractory leukemia and large b-cell lymphoma. In some instances complications of the therapy have been observed. Two of the most prevalent complications are Cytokine Release Syndrome (CRS) and Immune effector Cell Associated Neurotoxicity Syndrome (ICANS). 

In 2019, the American Society for Transplantation and Cellular Therapy (ASTCT) published a paper regarding the formal consensus for grading both CRS and ICANS. With this new consensus on grading, unique ICD-10-CM diagnosis codes were created to more effectively track the severity of patient symptoms in response to immune effector cell (IEC) therapy. 

The following table summarizes the new grading based on the consensus paper in the References. For additional information, see the consensus paper (see References below).

CRS Consensus Grading Table

CRS Parameter

Grade 1 (D89.831)

Grade 2 (D89.832)

Grade 3 (D89.833)

Grade 4 (D89.834)

Fever1

Temperature >38° C

Temperature >38° C

Temperature >38° C

Temperature >38° C

 

With

Hypotension

None

Not requiring vasopressors

Requiring a vasopressor with or without vasopressin

Requiring multiple vasopressors (excluding vasopressin)

 

And/or2

Hypoxia

None

Requiring low-flow nasal cannula3 or blow-by

Requiring high-flow nasal cannula3, facemask, nonrebreather mask, or Venturi mask

Requiring positive pressure (eg, CPAP, BiPAP, intubation and mechanical ventilation)

Notes:

  1. Fever is defined as temperature ≥38°C not attributable to any other cause. In patients who have CRS then receive antipyretic or anticytokine therapy such as tocilizumab or steroids, fever is no longer required to grade subsequent CRS severity. In this case, CRS grading is driven by hypotension and/or hypoxia.
  2. CRS grade is determined by the more severe event: hypotension or hypoxia not attributable to any other cause. For example, a patient with temperature of 39.5°C, hypotension requiring 1 vasopressor, and hypoxia requiring low-flow nasal cannula is classified as grade 3 CRS.
  3. Low-flow nasal cannula is defined as oxygen delivered at ≤6L/minute. Low flow also includes blow-by oxygen delivery, sometimes used in pediatrics.
  4. High-flow nasal cannula is defined as oxygen delivered at >6L/minute.
  5. Grade 5 (G89.8335) is defined as death due to CRS in which another cause is not the principle factor leading to this outcome.

It should be noted that, although ICD-10-CM codes were requested which further describe the grade levels for Immune effector cell-associated neurotoxicity syndrome (ICANS), at the time of publication there are no new codes for that syndrome. 

ICD-10-CM instructional notes specify that any underlying cause (e.g., complications following infusion and therapeutic injection [T80.89-], complications of transplanted organs and tissue [T86.-]) should be coded before using these new D89.83- codes. Associated manifestations should also be coded.

###

Questions, comments?

If you have questions or comments about this article please contact us.  Comments that provide additional related information may be added here by our Editors.


Latest articles:  (any category)

Billing and Documenting for Therapeutic Exercises versus Therapeutic Activities
July 13th, 2022 - Dr. Evan M. Gwilliam, DC, MBA, QCC, CPC, CCPC, CPMA, CPCO, AAPC Fellow, Clinical Director
Chiropractors treat, among other things, issues with the musculoskeletal system. Active therapeutic procedures are accepted as effective ways to treat many common conditions and therefore can be billed and generate revenue for a clinic. Two common CPT codes that might be used in a chiropractic setting include:
Medicare Advantage (MA) Benchmarking Policies Are Headed for Change
July 12th, 2022 - Aimee L. Wilcox, CPMA, CCS-P, CST, MA, MT
More than 43% of Medicare beneficiaries are not enrolled in Medicare Advantage plans, which were established to control costs and improve quality. However, as noted in the March MedPac Report Executive Summary of 2021, these plans average an estimated 104% of Medicare Fee-For-Service (FFS) spending. How does CMS plan to manage Medicare Advantage plans now?
How Extensions to the COVID-19 Public Health Emergency Affect Healthcare Reimbursement
June 28th, 2022 - Aimee L. Wilcox, CPMA, CCS-P, CST, MA, MT
Providers need to begin preparations for how to handle a return to pre-COVID-19 public health emergency (PHE) policies. As the saying goes, "you can't put the rabbit back in the hat." Some COVID-19 PHE policies are so well liked it will be very difficult for the government to return to pre-COVID-19 policies. For now, we have at least the promise of a 60-day notice to all governors precipitating the end of the PHE.
Why You Should Be Using The Two-Midnight Rule
June 23rd, 2022 - David M. Glaser, Esq.
Are you using something other than two-midnight? Here’s why you shouldn’t be. Is there the possibility that your utilization management team and physician advisors are applying InterQual, MCG, or any other utilization tool other than the two-midnight rule to your Medicare admissions? Over the last few months, it has...
Q/A: Service Period for 99490
June 6th, 2022 - Chris Woolstenhulme
Question: If CCM hours/work is to be billed monthly, and CCM tasks are done daily throughout the month, should it be saved until the end of the month to bill, and should each date be billed as DOS in one claim? Answer: According to CMS, “The service period for CPT 99490 ...
Reporting CCM and TCM Codes with E/M Codes
June 1st, 2022 - Chris Woolstenhulme
When reporting CCM or TCM codes, you will only get reimbursed for what is allowed. The E/M office visits can be coded in addition but are not interchangeable with CCM codes. You can bill an E/M visit during the time a patient is under Care Management, however, you can’t count time ...
Q/A: Billing Over the Allowed Amount
June 1st, 2022 - Chris Woolstenhulme
Question: Is there a financial penalty for billing over the allowed amount? Answer: Yes, if you are submitting claims to a contracted provider, you cannot bill over the contracted amount of your fee schedule. This is called balanced billing. There is also the no-surprise rule that protects insured and non-insured or ...



Home About Contact Terms Privacy

innoviHealth® - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain)

Copyright © 2000-2022 innoviHealth Systems®, Inc. - CPT® copyright American Medical Association